The vicious cycle of dry eye disease: a look into promising novel drug therapies

References

• Stapleton F, Alves M, Bunya VY, et al. TFOS DEWS II epidemiology report. Ocul Surf. 2017;15:334–365. doi: 10.1016/j.jtos.2017.05.003
   PubMed Web of Science ®Google Scholar
• Wolffsohn JS, Arita R, Chalmers R, et al. TFOS DEWS II diagnostic methodology report. Ocul Surf. 2017;15:539–574. doi: 10.1016/j.jtos.2017.05.001
   PubMed Web of Science ®Google Scholar
• Benítez-Del-Castillo J, Labetoulle M, Baudouin C, et al. Visual acuity and quality of life in dry eye disease: proceedings of the OCEAN group meeting. Ocul Surf. 2017;15:169–178. doi: 10.1016/j.jtos.2016.11.003
   PubMed Web of Science ®Google Scholar
• Rolando M, Iester M, Macrí A, et al. Low spatial-contrast sensitivity in dry eyes. Cornea. 1998;17(4):376–379. doi: 10.1097/00003226-199807000-00006
   PubMed Web of Science ®Google Scholar
• Uchino M, Schaumberg DA. Dry eye disease: impact on quality of life and vision. Curr Ophthalmol Rep. 2013;1(2):51–57. doi: 10.1007/s40135-013-0009-1
   PubMedGoogle Scholar
• Carnt NA, Keay L, Naduvilath T, et al. Risk factors associated with corneal inflammation in soft contact lens daily wear. Invest Ophthalmol Vis Sci. 2007;48:4326–4326.
   Google Scholar
• Nichols KK, Redfern RL, Jacob JT, et al. The TFOS International Workshop on contact lens discomfort: report of the definition and classification subcommittee. Invest Ophthalmol Vis Sci. 2013;54(11):TFOS14–TFOS19. doi: 10.1167/iovs.13-13074
   PubMed Web of Science ®Google Scholar
• van Setten G, Labetoulle M, Baudouin C, et al. Evidence of seasonality and effects of psychrometry in dry eye disease. Acta Ophthalmol. 2016;94(5):499–506. doi: 10.1111/aos.12985
   PubMed Web of Science ®Google Scholar
• Labetoulle M, Benitez-Del-Castillo JM, Barabino S, et al. Artificial tears: biological role of their ingredients in the management of dry eye disease. IJMS. 2022 Mar 1;23(5):2434. Epub ahead of print. doi: 10.3390/IJMS23052434
   Google Scholar
• Jones L, Downie LE, Korb D, et al. TFOS DEWS II management and therapy report. Ocul Surf. 2017;15:575–628. doi: 10.1016/j.jtos.2017.05.006
   PubMed Web of Science ®Google Scholar
• Barabino S, Benitez-Del-Castillo JM, Fuchsluger T, et al. Dry eye disease treatment: the role of tear substitutes, their future, and an updated classification. Eur Rev Med Pharmacol Sci. 2020;24(17):8642–8652. doi: 10.26355/eurrev_202009_22801
   PubMed Web of Science ®Google Scholar
• Mohamed HB, Abd El-Hamid BN, Fathalla D, et al. Current trends in pharmaceutical treatment of dry eye disease: a review. Eur J Pharm Sci. 2022 Aug 1;175. Epub ahead of print. doi: 10.1016/J.EJPS.2022.106206
   PubMed Web of Science ®Google Scholar
• Aragona P, Giannaccare G, Mencucci R, et al. Modern approach to the treatment of dry eye, a complex multifactorial disease: a P.I.C.A.S.S.O. board review. Br J Ophthalmol. 2021;105(4):446–453. doi: 10.1136/bjophthalmol-2019-315747
   PubMed Web of Science ®Google Scholar
• Bron AJ, de Paiva CS, Chauhan SK, et al. TFOS DEWS II pathophysiology report. Ocul Surf. 2017;15:438–510. doi: 10.1016/j.jtos.2017.05.011
   PubMed Web of Science ®Google Scholar
• Aragona P, Rolando M. Towards a dynamic customised therapy for ocular surface dysfunctions. Br J Ophthalmol. 2013;97(8):955–960. doi: 10.1136/bjophthalmol-2012-302568
   PubMed Web of Science ®Google Scholar
• Mantelli F, Argüeso P. Functions of ocular surface mucins in health and disease. Curr Opin Allergy Clin Immunol. 2008;8(5):477–483. doi: 10.1097/ACI.0b013e32830e6b04
   PubMed Web of Science ®Google Scholar
• Braun RJ, King-Smith PE, Begley CG, et al. Dynamics and function of the tear film in relation to the blink cycle. Prog Retin Eye Res. 2015;45:132–164. doi: 10.1016/j.preteyeres.2014.11.001
   PubMed Web of Science ®Google Scholar
• Rolando M, Refojo MF, Kenyon KR. Tear water evaporation and eye surface diseases. Ophthalmologica. 1985;190(3):147–149. doi: 10.1159/000309511
   PubMed Web of Science ®Google Scholar
• Craig JP, Tomlinson A. Importance of the lipid layer in human tear film stability and evaporation. Optom Vis Sci. 1997;74(1):8–13. doi: 10.1097/00006324-199701000-00014
   PubMed Web of Science ®Google Scholar
• Stepp MA, Tadvalkar G, Hakh R, et al. Corneal epithelial cells function as surrogate Schwann cells for their sensory nerves. Glia. 2017;65(6):851–863. doi: 10.1002/glia.23102
   PubMed Web of Science ®Google Scholar
• Lemp MA, Baudouin C, Baum J, et al. The definition and classification of dry eye disease: report of the definition and classification subcommittee of the International dry eye WorkShop (2007). Ocul Surf. 2007;5:75–92.
   PubMed Web of Science ®Google Scholar
• Musumeci M, Aragona P, Bellin M, et al. Acidic mammalian chitinase in dry eye conditions. Cornea. 2009;28(6):667–672. doi: 10.1097/ICO.0b013e31819bc308
   PubMed Web of Science ®Google Scholar
• Solomon A, Dursun D, Liu Z, et al. Pro- and anti-inflammatory forms of interleukin-1 in the tear fluid and conjunctiva of patients with dry-eye disease. Invest Ophthalmol Vis Sci. 2001;42:2283–2292.
   PubMed Web of Science ®Google Scholar
• De Paiva CS, Corrales RM, Villarreal AL, et al. Corticosteroid and doxycycline suppress MMP-9 and inflammatory cytokine expression, MAPK activation in the corneal epithelium in experimental dry eye. Exp Eye Res. 2006;83(3):526–535. doi: 10.1016/j.exer.2006.02.004
   PubMed Web of Science ®Google Scholar
• Massingale ML, Li X, Vallabhajosyula M, et al. Analysis of inflammatory cytokines in the tears of dry eye patients. Cornea. 2009;28(9):1023–1027. doi: 10.1097/ICO.0b013e3181a16578
   PubMed Web of Science ®Google Scholar
• Musumeci M, Bellin M, Maltese A, et al. Chitinase levels in the tears of subjects with ocular allergies. Cornea. 2008;27(2):168–173. doi: 10.1097/ICO.0b013e318159a950
   PubMed Web of Science ®Google Scholar
• Vereertbrugghen A, Galletti JG. Corneal nerves and their role in dry eye pathophysiology. Exp Eye Res. 2022 Sep 1;222. Epub ahead of print. doi: 10.1016/J.EXER.2022.109191
   PubMed Web of Science ®Google Scholar
• Sambhi RDS, Sambhi GDS, Mather R, et al. Dry eye after refractive surgery: a meta-analysis. Canadian Journal Of Ophthalmology. 2020;55(2):99–106. doi: 10.1016/j.jcjo.2019.07.005
   PubMed Web of Science ®Google Scholar
• Miura M, Inomata T, Nakamura M, et al. Prevalence and characteristics of dry eye disease after cataract surgery: a systematic review and meta-analysis. Ophthalmol Ther. 2022;11(4):1309. doi: 10.1007/s40123-022-00513-y
   PubMed Web of Science ®Google Scholar
• Chen H, Feng X, Niu G, et al. Evaluation of dry eye after implantable collamer lens surgery. Ophthalmic Res. 2021;64(3):356–362. doi: 10.1159/000511197
   PubMed Web of Science ®Google Scholar
• Nepp J, Abela C, Polzer I, et al. Is there a correlation between the severity of diabetic retinopathy and keratoconjunctivitis sicca? Cornea. 2000;19(4):487–491. doi: 10.1097/00003226-200007000-00017
   PubMed Web of Science ®Google Scholar
• Achtsidis V, Eleftheriadou I, Kozanidou E, et al. Dry eye syndrome in subjects with diabetes and association with neuropathy. Diabetes Care. 2014;37(10):e210–e211. doi: 10.2337/dc14-0860
   PubMed Web of Science ®Google Scholar
• Lv H, Li A, Zhang X, et al. Meta-analysis and review on the changes of tear function and corneal sensitivity in diabetic patients. Acta Ophthalmol. 2014 Mar;92(2):e96–e104. Epub ahead of print. doi: 10.1111/AOS.12063
   PubMed Web of Science ®Google Scholar
• Rodriguez JD, Lane KJ, Ousler GW, et al. Blink: characteristics, controls, and relation to dry eyes. Curr Eye Res. 2018;43(1):52–66. doi: 10.1080/02713683.2017.1381270
   PubMed Web of Science ®Google Scholar
• Ayaki M, Kawashima M, Negishi K, et al. High prevalence of sleep and mood disorders in dry eye patients: survey of 1,000 eye clinic visitors. Neuropsychiatr Dis Treat. 2015;11:889. doi: 10.2147/NDT.S81515
   PubMed Web of Science ®Google Scholar
• Kawashima M, Uchino M, Yokoi N, et al. The association between dry eye disease and physical activity as well as sedentary behavior: results from the Osaka study. Journal Of Ophthalmology Epub ahead of print 2014. 2014;2014:1–6. doi: 10.1155/2014/943786
   Web of Science ®Google Scholar
• Baudouin C, Aragona P, Van Setten G, et al. Diagnosing the severity of dry eye: a clear and practical algorithm. Br J Ophthalmol. 2014;98(9):1168–1176. doi: 10.1136/bjophthalmol-2013-304619
   PubMed Web of Science ®Google Scholar
• Bartlett JD, Keith MS, Sudharshan L, et al. Associations between signs and symptoms of dry eye disease: a systematic review. Clin Ophthalmol. 2015;9:1719. doi: 10.2147/OPTH.S89700
   PubMed Web of Science ®Google Scholar
• Pflugfelder SC, Maskin SL, Anderson B, et al. A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance. Am J Ophthalmol. 2004;138(3):444–457. doi: 10.1016/j.ajo.2004.04.052
   PubMed Web of Science ®Google Scholar
• Marsh P, Pflugfelder SC. Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in sjögren syndrome. Ophthalmol. 1999;106(4):811–816. doi: 10.1016/S0161-6420(99)90171-9
   PubMed Web of Science ®Google Scholar
• Aragona P, Spinella R, Rania L, et al. Safety and efficacy of 0.1% clobetasone butyrate eyedrops in the treatment of dry eye in sjögren syndrome. Eur J Ophthalmol. 2013;23(3):368–376. doi: 10.5301/ejo.5000229
   PubMed Web of Science ®Google Scholar
• Susarla R, Liu L, Walker EA, et al. Cortisol biosynthesis in the human ocular surface innate immune response. PLoS One. 2014;9(4):e94913. doi: 10.1371/journal.pone.0094913
   PubMed Web of Science ®Google Scholar
• Sullivan DA, Rocha EM, Aragona P, et al. TFOS DEWS II sex, gender, and hormones report. Ocul Surf. 2017;15:284–333. doi: 10.1016/j.jtos.2017.04.001
   PubMed Web of Science ®Google Scholar
• Rolando M, Vagge A. Safety and efficacy of Cortisol Phosphate in hyaluronic acid vehicle in the treatment of dry eye in Sjogren syndrome. J Ocul Pharmacol Ther. 2017;33(5):383–390. doi: 10.1089/jop.2016.0147
   PubMed Web of Science ®Google Scholar
• Moya AG, Parra AP, Sancho S, et al. 4CPS-323 Evaluation of the use, adherence and tolerance of 0.03% tacrolimus eye drops. Eur J Hosp Pharm. 2021;28:A76–A76.
   PubMedGoogle Scholar
• Aragona P. Topical cyclosporine: are all indications justified? Br J Ophthalmol. 2014;98:1001–1002. doi: 10.1136/bjophthalmol-2013-304728
   PubMed Web of Science ®Google Scholar
• Barabino S, Horwath-Winter J, Messmer EM, et al. The role of systemic and topical fatty acids for dry eye treatment. Prog Retin Eye Res. 2017;61:23–34. doi: 10.1016/j.preteyeres.2017.05.003
   PubMed Web of Science ®Google Scholar
• Giannaccare G, Pellegrini M, Sebastiani S, et al. Efficacy of omega-3 fatty acid supplementation for treatment of dry eye disease: a meta-analysis of randomized clinical trials. Cornea. 2019;38(5):565–573. doi: 10.1097/ICO.0000000000001884
   PubMed Web of Science ®Google Scholar
• Haber SL, Benson V, Buckway CJ, et al. Lifitegrast: a novel drug for patients with dry eye disease. Ther Adv Ophthalmol. 2019;11:251584141987036. doi: 10.1177/2515841419870366
   Web of Science ®Google Scholar
• Cortina MS, He J, Li N, et al. Neuroprotectin D1 synthesis and corneal nerve regeneration after experimental surgery and treatment with PEDF plus DHA. Invest Ophthalmol Vis Sci. 2010;51(2):804. doi: 10.1167/iovs.09-3641
   PubMed Web of Science ®Google Scholar
• Perez VL, Pflugfelder SC, Zhang S, et al. Lifitegrast, a novel integrin antagonist for treatment of dry eye disease. Ocul Surf. 2016;14(2):207–215. doi: 10.1016/j.jtos.2016.01.001
   PubMed Web of Science ®Google Scholar
• Moscovici BK, Holzchuh R, Chiacchio BB, et al. Clinical treatment of dry eye using 0.03% tacrolimus eye drops. Cornea. 2012;31(8):945–949. doi: 10.1097/ICO.0b013e31823f8c9b
   PubMed Web of Science ®Google Scholar
• Cejka C, Kubinova S, Čejková J. Trehalose in ophthalmology. Histol Histopathol. 2019;34:611–618. doi: 10.1155/2019/1857086
   PubMed Web of Science ®Google Scholar
• Guo N, Puhlev I, Brown DR, et al. Trehalose expression confers desiccation tolerance on human cells. Nat Biotechnol. 2000;18(2):168–171. doi: 10.1038/72616
   PubMed Web of Science ®Google Scholar
• Fariselli C, Giannaccare G, Fresina M, et al. Trehalose/Hyaluronate eyedrop effects on ocular surface inflammatory markers and mucin expression in dry eye patients. Clin Ophthalmol. 2018;12:1293. doi: 10.2147/OPTH.S174290
   PubMed Web of Science ®Google Scholar
• Sarkar S, Davies JE, Huang Z, et al. Trehalose, a novel mTOR-independent autophagy enhancer, accelerates the clearance of mutant huntingtin and alpha-synuclein. J Biol Chem. 2007;282:5641–5652. doi: 10.1074/jbc.M609532200
   PubMed Web of Science ®Google Scholar
• Yancey PH. Organic osmolytes as compatible, metabolic and counteracting cytoprotectants in high osmolarity and other stresses. J Exp Biol. 2005;208(15):2819–2830. doi: 10.1242/jeb.01730
   PubMed Web of Science ®Google Scholar
• García-López C, Gómez-Huertas C, Sánchez-González JM, et al. Opioids and ocular surface pathology: a literature review of new treatments horizons. J Clin Med. 2022;11(5):1424 Epub ahead of print. doi: 10.3390/JCM11051424
   PubMed Web of Science ®Google Scholar
• Abdelkader H, Ismail S, Kamal A, et al. Design and evaluation of controlled-release niosomes and discomes for naltrexone hydrochloride ocular delivery. J Pharm Sci. 2011;100(5):1833–1846. doi: 10.1002/jps.22422
   PubMed Web of Science ®Google Scholar
• Shen G, Qi Q, Ma X. Effect of moisture chamber spectacles on tear functions in dry eye disease. Optom Vis Sci. 2016;93(2):158–164. doi: 10.1097/OPX.0000000000000778
   PubMed Web of Science ®Google Scholar
• Erdinest N, Pincovich S, London N, et al. Neurostimulation for dry eye disease. Curr Opin Allergy Clin Immunol. 2022;22(5):328–334. doi: 10.1097/ACI.0000000000000841
   PubMed Web of Science ®Google Scholar
• Samudre S, Lattanzio FA, Lossen V, et al. Lacritin, a novel human tear glycoprotein, promotes sustained basal tearing and is well tolerated. Invest Ophthalmol Vis Sci. 2011;52(9):6265. doi: 10.1167/iovs.10-6220
   PubMed Web of Science ®Google Scholar
• Schmidt TA, Sullivan DA, Knop E, et al. Transcription, translation, and function of Lubricin, a boundary lubricant, at the ocular surface. JAMA Ophthalmol. 2013;131(6):766–776. doi: 10.1001/jamaophthalmol.2013.2385
   PubMed Web of Science ®Google Scholar
• McNamara NA, Ge S, Lee SM, et al. Reduced levels of tear lacritin are associated with corneal neuropathy in patients with the ocular component of Sjögren’s syndrome. Invest Ophthalmol Vis Sci. 2016;57(13):5237–5243. doi: 10.1167/iovs.16-19309
   PubMed Web of Science ®Google Scholar
• Lambiase A, Sullivan BD, Schmidt TA, et al. A two-week, randomized, double-masked study to evaluate safety and efficacy of Lubricin (150 μg/mL) eye drops versus sodium hyaluronate (HA) 0.18% eye drops (Vismed®) in patients with moderate dry eye disease. Ocul Surf. 2017;15(1):77–87. doi: 10.1016/j.jtos.2016.08.004
   PubMed Web of Science ®Google Scholar
• Dilly PN. Contribution of the epithelium to the stability of the tear film. Trans Ophthalmol Soc U K. 1985;104(Pt 4):381–389.
   PubMedGoogle Scholar
• Koo BS, Lee DY, Ha HS, et al. Comparative analysis of the tear protein expression in blepharitis patients using two-dimensional electrophoresis. J Proteome Res. 2005;4(3):719–724. doi: 10.1021/pr0498133
   PubMed Web of Science ®Google Scholar
• Nichols JJ, Green-Church KB. Mass spectrometry-based proteomic analyses in contact lens-related dry eye. Cornea. 2009;28(10):1109–1117. doi: 10.1097/ICO.0b013e3181a2ad81
   PubMed Web of Science ®Google Scholar
• Vijmasi T, Chen FYT, Balasubbu S, et al. Topical administration of lacritin is a novel therapy for aqueous-deficient dry eye disease. Invest Ophthalmol Vis Sci. 2014;55(8):5401–5409. doi: 10.1167/iovs.14-13924
   PubMed Web of Science ®Google Scholar
• Aluru SV, Agarwal S, Srinivasan B, et al. Lacrimal proline rich 4 (LPRR4) protein in the tear fluid is a potential biomarker of dry eye syndrome. PLoS One. 2012;7(12):e51979. doi: 10.1371/journal.pone.0051979
   PubMed Web of Science ®Google Scholar
• Torkildsen GL, Pattar GR, Jerkins G, et al. Efficacy and safety of single-dose OC-02 (Simpinicline solution) nasal spray on signs and symptoms of dry eye disease: the PEARL phase II randomized trial. Clin Ther. 2022;44(9):1178–1186. doi: 10.1016/j.clinthera.2022.07.006
   PubMed Web of Science ®Google Scholar
• Frampton JE. Varenicline solution nasal spray: a review in dry eye disease. Drugs. 2022;82(14):1481–1488. doi: 10.1007/s40265-022-01782-4
   PubMed Web of Science ®Google Scholar
• Hori Y. Secreted mucins on the ocular surface. Invest Ophthalmol Vis Sci. 2018;59(14):DES151–DES156. doi: 10.1167/iovs.17-23623
   PubMed Web of Science ®Google Scholar
• Gipson IK, Hori Y, Argüeso P. Character of ocular surface mucins and their alteration in dry eye disease. Ocul Surf. 2004;2(2):131–148. doi: 10.1016/S1542-0124(12)70149-0
   PubMedGoogle Scholar
• Koh S. Clinical utility of 3% diquafosol ophthalmic solution in the treatment of dry eyes. Clin Ophthalmol. 2015;9:865. doi: 10.2147/OPTH.S69486
   PubMed Web of Science ®Google Scholar
• Zhang Q, Zhang H, Qin G, et al. Impact of diquafosol ophthalmic solution on tear film and dry eye symptom in type 2 diabetic dry eye: a pilot study. J Ocul Pharmacol Ther. 2022;38(2):133–140. doi: 10.1089/jop.2021.0083
   PubMed Web of Science ®Google Scholar
• Katagiri A, Tsubota K, Mikuzuki L, et al. Tear secretion by diquafosol suppresses the excitability of trigeminal brainstem nuclear complex neurons by reducing excessive P2Y2 expression in the trigeminal ganglion in dry eye rats. Neurosci Res. 2023;191:66–76. doi: 10.1016/j.neures.2023.01.003
   PubMed Web of Science ®Google Scholar
• Katagiri A, Tsubota K, Mikuzuki L, et al. Diquafosol sodium reduces neuronal activity in trigeminal subnucleus caudalis in a rat model of chronic dry eye disease. Neurosci Lett. 2023 Jan 1;792. Epub ahead of print. doi: 10.1016/J.NEULET.2022.136939
   PubMed Web of Science ®Google Scholar
• Sun X, Liu L, Liu C. Topical diquafosol versus hyaluronic acid for the treatment of dry eye disease: a meta-analysis of randomized controlled trials. Graefes Arch Clin Exp Ophthalmol. 2023. Epub ahead of print. doi: 10.1007/S00417-023-06083-4
   Web of Science ®Google Scholar
• Kinoshita S, Oshiden K, Awamura S, et al. A randomized, multicenter phase 3 study comparing 2% rebamipide (OPC-12759) with 0.1% sodium hyaluronate in the treatment of dry eye. Ophthalmol. 2013;120(6):1158–1165. doi: 10.1016/j.ophtha.2012.12.022
   PubMed Web of Science ®Google Scholar
• Jain P, Li R, Lama T, et al. An NGF mimetic, MIM-D3, stimulates conjunctival cell glycoconjugate secretion and demonstrates therapeutic efficacy in a rat model of dry eye. Exp Eye Res. 2011;93(4):503–512. doi: 10.1016/j.exer.2011.06.014
   PubMed Web of Science ®Google Scholar
• Meerovitch K, Torkildsen G, Lonsdale J, et al. Safety and efficacy of MIM-D3 ophthalmic solutions in a randomized, placebo-controlled phase 2 clinical trial in patients with dry eye. Clin Ophthalmol. 2013;7:1275–1285. doi: 10.2147/OPTH.S44688
   PubMedGoogle Scholar
• Mito C, Tokushige H, Kida T, et al. Ecabet sodium promotes MUC5AC secretion in rabbit tears. Invest Ophthalmol Vis Sci. 2007;48:384–384.
   Google Scholar
• Lee H, Jeon S, Kim CE, et al. A new ophthalmic pharmaceutical formulation, topical Sulglycotide, enhances the ocular mucin secretion in desiccation stress-mediated dry eye disease. Invest Ophthalmol Vis Sci. 2019;60(4):1076–1087. doi: 10.1167/iovs.18-24935
   PubMed Web of Science ®Google Scholar
• Dota A, Takaoka-Shichijo Y, Nakamura M. Gefarnate stimulates mucin-like glycoprotein secretion in conjunctival tissue and ameliorates corneal epithelial damage in animal dry-eye models. Clin Ophthalmol. 2013;7:211–217. doi: 10.2147/OPTH.S39061
   PubMedGoogle Scholar
• Gamache DA, Wei ZY, Weimer LK, et al. Corneal protection by the ocular mucin secretagogue 15(S)-HETE in a rabbit model of desiccation-induced corneal defect. J Ocul Pharmacol Ther. 2002;18(4):349–361. doi: 10.1089/10807680260218515
   PubMed Web of Science ®Google Scholar
• Beckman K, Katz J, Majmudar P, et al. Loteprednol Etabonate for the treatment of dry eye disease. J Ocul Pharmacol Ther. 2020;36(7):497–511. doi: 10.1089/jop.2020.0014
   PubMed Web of Science ®Google Scholar
• Wirta DL, Torkildsen GL, Moreira HR, et al. A clinical phase II study to assess efficacy, safety, and tolerability of waterfree cyclosporine formulation for treatment of dry eye disease. Ophthalmol. 2019;126(6):792–800. doi: 10.1016/j.ophtha.2019.01.024
   PubMed Web of Science ®Google Scholar
• Shettle L, McLaurin E, Martel J, et al. Topical anti-TNFα agent Licaminlimab (OCS-02) relieves persistent ocular discomfort in severe dry eye disease: a randomized phase II study. Clin Ophthalmol. 2022;16:2167–2177. doi: 10.2147/OPTH.S366836
   PubMed Web of Science ®Google Scholar
• Brereton HM, Taylor SD, Farrall A, et al. Influence of format on in vitro penetration of antibody fragments through porcine cornea. Br J Ophthalmol. 2005;89:1205. doi: 10.1136/bjo.2005.066225
   PubMed Web of Science ®Google Scholar
• Lambiase A, Manni L, Bonini S, et al. Nerve growth factor promotes corneal healing: structural, biochemical, and molecular analyses of rat and human corneas. Invest Ophthalmol Vis Sci. 2000;41:1063–1069.
   PubMed Web of Science ®Google Scholar
• Lee HK, Ryu IH, Seo KY, et al. Topical 0.1% prednisolone lowers nerve growth factor expression in keratoconjunctivitis sicca patients. Ophthalmol. 2006;113(2):198–205. doi: 10.1016/j.ophtha.2005.09.033
   PubMed Web of Science ®Google Scholar
• Kim SY, Choi JS, Joo CK. Effects of nicergoline on corneal epithelial wound healing in rat eyes. Invest Ophthalmol Vis Sci. 2009;50(2):621–625. doi: 10.1167/iovs.08-2037
   PubMed Web of Science ®Google Scholar
• Coco G, Piccotti G, Romano V, et al. Cenegermin for the treatment of dry eye disease. Drugs Today (Barc). 2023;59:113–123.
   PubMed Web of Science ®Google Scholar
• Lambiase A, Rama P, Bonini S, et al. Topical treatment with nerve growth factor for corneal neurotrophic ulcers. N Engl J Med. 1998;43:372–373.
   Google Scholar
• Lambiase A, Bonini S, Aloe L, et al. Anti-inflammatory and healing properties of nerve growth factor in immune corneal ulcers with stromal melting. Arch Ophthalmol. 2000;118:1446–1449. doi: 10.1001/archopht.118.10.1446
   PubMed Web of Science ®Google Scholar
• Bonini S, Lambiase A, Rama P, et al. Topical treatment with nerve growth factor for neurotrophic keratitis. Ophthalmol. 2000;107:1347–1351. doi: 10.1016/S0161-6420(00)00163-9
   PubMed Web of Science ®Google Scholar
• Sacchetti M, Lambiase A, Schmidl D, et al. Effect of recombinant human nerve growth factor eye drops in patients with dry eye: a phase IIa, open label, multiple-dose study. Br J Ophthalmol. 2020;104:127–135. doi: 10.1136/bjophthalmol-2018-312470
   PubMed Web of Science ®Google Scholar
• Sosne G, Qiu P, Kurpakus-Wheater M. Thymosin beta 4: a novel corneal wound healing and anti-inflammatory agent. Clin Ophthalmol. 2007;1:201.
   PubMedGoogle Scholar
• Sosne G, Dunn SP, Kim C. Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial. Cornea. 2015;34(5):491–496. doi: 10.1097/ICO.0000000000000379
   PubMed Web of Science ®Google Scholar
• Kovalchin J, King B, Masci A, et al. Preclinical development of EBI-005: an IL-1 receptor-1 inhibitor for the topical ocular treatment of ocular surface inflammatory diseases. Eye Contact Lens. 2018;44:170–181. doi: 10.1097/ICL.0000000000000414
   PubMed Web of Science ®Google Scholar
• Goldstein MH, Martel JR, Sall K, et al. Multicenter study of a novel topical interleukin-1 receptor inhibitor, Isunakinra, in subjects with moderate to severe dry eye disease. Eye Contact Lens. 2017;43:287–296. doi: 10.1097/ICL.0000000000000276
   PubMed Web of Science ®Google Scholar
• Baiula M, Spampinato S. Experimental pharmacotherapy for dry eye disease: a review. J Exp Pharmacol. 2021;13:345–358. doi: 10.2147/JEP.S237487
   PubMedGoogle Scholar
• Hesselink JMK, Chiosi F, Costagliola C. Resolvins and aliamides: lipid autacoids in ophthalmology - what promise do they hold? Drug Des Devel Ther. 2016;10:3133–3141. doi: 10.2147/DDDT.S112389
   PubMed Web of Science ®Google Scholar
• Cholkar K, Gilger BC, Mitra AK. Topical delivery of aqueous micellar resolvin E1 analog (RX-10045). Int J Pharm. 2016;498(1–2):326–334. doi: 10.1016/j.ijpharm.2015.12.037
   PubMed Web of Science ®Google Scholar
• Li N, He J, Gjorstrup P, et al. The Resolvin E1 analogs, RX-10065 and RX-10005 Improve tear production and decrease inflammation in a Mouse dry eye model. Invest Ophthalmol Vis Sci. 2008;49:121–121.
   Google Scholar
• Tsubota K, Kawashima M, Inaba T, et al. The antiaging approach for the treatment of dry eye. Cornea. Nov 2021 Nov;31 Suppl 1(Supplement 1):S3–S8. Epub ahead of print. doi: 10.1097/ICO.0B013E31826A05A8
   PubMedGoogle Scholar
• Skulachev VP. Cationic antioxidants as a powerful tool against mitochondrial oxidative stress. Biochem Biophys Res Commun. 2013;441(2):275–279. doi: 10.1016/j.bbrc.2013.10.063
   PubMed Web of Science ®Google Scholar
• Brzheskiy VV, Efimova EL, Vorontsova TN, et al. Results of a multicenter, randomized, double-masked, placebo-controlled clinical study of the efficacy and safety of Visomitin eye drops in patients with dry eye syndrome. Adv Ther. 2015;32:1263–1279. doi: 10.1007/s12325-015-0273-6
   PubMed Web of Science ®Google Scholar
• Petrov A, Perekhvatova N, Skulachev M, et al. SkQ1 ophthalmic solution for dry eye treatment: results of a phase 2 safety and efficacy clinical study in the environment and during challenge in the controlled adverse environment model. Adv Ther. 2016;33(1):96–115. doi: 10.1007/s12325-015-0274-5
   PubMed Web of Science ®Google Scholar
• Levin MH, Jung KK, Hu J, et al. Potential difference measurements of ocular surface Na+ absorption analyzed using an electrokinetic model. Invest Ophthalmol Vis Sci. 2006;47:306–316. doi: 10.1167/iovs.05-1082
   PubMed Web of Science ®Google Scholar
• Hara S, Hazama A, Miyake M, et al. The effect of topical amiloride eye drops on tear quantity in rabbits. Mol Vis. 2010;16:2279.
   PubMed Web of Science ®Google Scholar
• Thelin WR, Johnson MR, Hirsh AJ, et al. Effect of topically applied epithelial sodium channel inhibitors on tear production in normal mice and in mice with induced aqueous tear deficiency. J Ocul Pharmacol Ther. 2012;28(4):433. doi: 10.1089/jop.2011.0157
   PubMed Web of Science ®Google Scholar
• Belmonte C, Nichols JJ, Cox SM, et al. TFOS DEWS II pain and sensation report. Ocul Surf. 2017;15:404–437. doi: 10.1016/j.jtos.2017.05.002
   PubMed Web of Science ®Google Scholar
• Parra A, Madrid R, Echevarria D, et al. Ocular surface wetness is regulated by TRPM8-dependent cold thermoreceptors of the cornea. Nat Med. 2010;16(12):1396–1399. doi: 10.1038/nm.2264
   PubMed Web of Science ®Google Scholar
• Wirta DL, Senchyna M, Lewis AE, et al. A randomized, vehicle-controlled, phase 2b study of two concentrations of the TRPM8 receptor agonist AR-15512 in the treatment of dry eye disease (COMET-1). Ocul Surf. 2022;26:166–173. doi: 10.1016/j.jtos.2022.08.003
   PubMed Web of Science ®Google Scholar
• Bourinet E, Altier C, Hildebrand ME, et al. Calcium-permeable ion channels in pain signaling. Physiol Rev. 2014;94(1):81–140. doi: 10.1152/physrev.00023.2013
   PubMed Web of Science ®Google Scholar
• Benitez-Del-Castillo JM, Moreno-Montañés J, Jiménez-Alfaro I, et al. Safety and efficacy clinical trials for SYL1001, a novel short interfering RNA for the treatment of dry eye disease. Invest Ophthalmol Vis Sci. 2016;57(14):6447–6454. doi: 10.1167/iovs.16-20303
   PubMed Web of Science ®Google Scholar
• Giannaccare G, Carnevali A, Senni C, et al. Umbilical cord blood and serum for the treatment of ocular diseases: a comprehensive review. Ophthalmol Ther. 2020;9(2):235–248. doi: 10.1007/s40123-020-00239-9
   PubMed Web of Science ®Google Scholar
• Lee MJ, Ko AY, Ko JH, et al. Mesenchymal stem/stromal cells protect the ocular surface by suppressing inflammation in an experimental dry eye. Mol Ther. 2015;23(1):139–146. doi: 10.1038/mt.2014.159
   PubMed Web of Science ®Google Scholar
• Jiang Y, Lin S, Gao Y. Mesenchymal stromal cell–based therapy for dry eye: current status and future perspectives. Cell Transplant. 2022 Jan 1;31. Epub ahead of print. doi: 10.1177/09636897221133818
   Google Scholar
• Pérez ML, Barreales S, Sabater-Cruz N, et al. Amniotic membrane extract eye drops: a new approach to severe ocular surface pathologies. Cell Tissue Bank. 2022;23(3):473–481. doi: 10.1007/s10561-021-09962-4
   PubMed Web of Science ®Google Scholar
• Yeu E, Goldberg DF, Mah FS, et al. Safety and efficacy of amniotic cytokine extract in the treatment of dry eye disease. Clin Ophthalmol. 2019;13:887. doi: 10.2147/OPTH.S203510
   PubMed Web of Science ®Google Scholar
• Barabino S, Chen Y, Chauhan S, et al. Ocular surface immunity: homeostatic mechanisms and their disruption in dry eye disease. Prog Retin Eye Res. 2012;31(3):271–285. doi: 10.1016/j.preteyeres.2012.02.003
   PubMed Web of Science ®Google Scholar
• Schmidl D, Szalai L, Kiss OG, et al. A phase II, multicenter, randomized, placebo-controlled, double-masked trial of a topical estradiol ophthalmic formulation in postmenopausal women with moderate-to-severe dry eye disease. Adv Ther. 2021;38:1975–1986. doi: 10.1007/s12325-021-01680-3
   PubMed Web of Science ®Google Scholar
• Alster Y, Epstein-Barash H, Rapaport H, et al. Lipogenic activity of selenium disulfide and its role in enhancing lipid production in meibomian glands. Invest Ophthalmol Vis Sci. 2021;62:693–693.
   Web of Science ®Google Scholar
• Epstein-Barash H, Rapaport H, Alster Y, et al. Keratolytic and keratostatic activity of selenium disulfide and its disease modifying role in meibomian gland disease. Invest Ophthalmol Vis Sci. 2021;62:692–692.
   Web of Science ®Google Scholar
• Borgia A, Raimondi R, Fossati G, et al. Device-based therapies as a boost of conventional treatment in dry eye disease. Expert Rev Ophthalmol. 2022;17(6):387–393. doi: 10.1080/17469899.2022.2147928
   Web of Science ®Google Scholar